W.G. Shaheen & Associates DBA Whitney & Co Invests $7.29 Million in Edwards Lifesciences Co. (NYSE:EW)

W.G. Shaheen & Associates DBA Whitney & Co acquired a new stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 110,477 shares of the medical research company's stock, valued at approximately $7,290,000.

Other large investors have also recently made changes to their positions in the company. Bank of New York Mellon Corp raised its stake in Edwards Lifesciences by 4.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company's stock valued at $1,827,347,000 after acquiring an additional 809,605 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Edwards Lifesciences by 57.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company's stock worth $622,695,000 after acquiring an additional 2,390,137 shares in the last quarter. AustralianSuper Pty Ltd lifted its holdings in Edwards Lifesciences by 17.8% during the 3rd quarter. AustralianSuper Pty Ltd now owns 3,273,416 shares of the medical research company's stock worth $216,013,000 after purchasing an additional 494,604 shares in the last quarter. Ownership Capital B.V. increased its position in shares of Edwards Lifesciences by 1.2% during the third quarter. Ownership Capital B.V. now owns 2,993,019 shares of the medical research company's stock valued at $197,509,000 after buying an additional 34,597 shares during the period. Finally, American Century Companies Inc. lifted its holdings in shares of Edwards Lifesciences by 2.1% in the second quarter. American Century Companies Inc. now owns 2,082,961 shares of the medical research company's stock worth $192,403,000 after buying an additional 43,247 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Up 0.0 %

EW stock traded up $0.03 during midday trading on Tuesday, reaching $69.92. The company's stock had a trading volume of 2,278,954 shares, compared to its average volume of 4,642,844. The firm has a market capitalization of $41.24 billion, a price-to-earnings ratio of 9.88, a PEG ratio of 3.81 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The stock has a fifty day simple moving average of $67.53 and a two-hundred day simple moving average of $76.02.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts' consensus estimates of $0.67. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences's revenue was up 8.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.59 EPS. On average, equities research analysts predict that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company's stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total value of $333,850.00. Following the transaction, the vice president now directly owns 46,936 shares of the company's stock, valued at $3,133,916.72. This represents a 9.63 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the company's stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 40,000 shares of company stock valued at $2,657,000 over the last ninety days. 1.27% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

EW has been the subject of several analyst reports. Royal Bank of Canada cut their price target on shares of Edwards Lifesciences from $85.00 to $75.00 and set an "outperform" rating for the company in a report on Tuesday, October 8th. StockNews.com cut Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Thursday, July 25th. JPMorgan Chase & Co. boosted their price objective on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a "neutral" rating in a report on Friday, October 25th. Evercore ISI dropped their target price on shares of Edwards Lifesciences from $76.00 to $70.00 and set an "in-line" rating for the company in a research report on Tuesday, October 1st. Finally, Sanford C. Bernstein raised Edwards Lifesciences from a "strong sell" rating to a "hold" rating in a report on Monday, October 28th. Seventeen investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $75.67.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.